7 recruiting, 6 completed, 4 unknown, 3 active not recruiting. 10 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 3, 2 Phase 4.
Follow Newly Diagnosed: new trials by email Literature Review of Newly Diagnosed trials Research Report on Newly Diagnosed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? CAR-T, ASCT - Multiple Myeloma, Newly Diagnosed | Phase 2 | Not yet recruiting | Xuzhou Medical University | 60 | 2025-07-15 | 2025-07-17 |
| A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible CAR-T - Multiple Myeloma, Newly Diagnosed | Not applicable | Not yet recruiting | Xuzhou Medical University | 35 | 2025-07-15 | 2025-07-17 |
| Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia VACl, VACh, VACl Alternating With VACh - Acute Myeloid Leukemia, Adult, Newly Diagnosed | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 172 | 2024-07-29 | 2025-11-19 |
| Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection Carfilzomib, Daratumumab, Lenalidomide - Newly Diagnosed, High Risk | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 59 | 2024-06-12 | 2025-06-12 |
| Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma Zanubrutinib combined with Obinutuzumab - Follicular Lymphoma, Newly Diagnosed | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 39 | 2024-03-31 | 2024-09-03 |
| Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Zanubrutinib, Lenalidomide, Obinutuzumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2024-01-01 | 2024-08-09 |
| Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma XPO1 inhibitor - nk/T-cell Lymphoma, Newly Diagnosed | Phase 2 | Recruiting | Chinese PLA General Hospital | 10 | 2023-05-01 | 2023-04-27 |
| Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax - Leukemia, Myeloid | Phase 1 | Completed | Molecular Partners AG | 80 | 2022-12-29 | 2026-09-25 |
| Shared Decision Making on Care Pathways and CAMs: A Pilot Study alternative medicine education consultation - Breast Cancer, Non-metastatic | Not applicable | Unknown | University Hospital, Grenoble | 100 | 2022-09-28 | 2023-05-16 |
| Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv) Daratumumab - Multiple Myeloma, Newly Diagnosed | Completed | iOMEDICO AG | 96 | 2022-07-06 | 2024-10-01 | |
| Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). daunomycin/Idarubicin+ Silybinin, daunomycin/Idarubicin - Acute Myeloid Leukemia, Newly Diagnosed | Phase 4 | Recruiting | Fujian Medical University Union Hospital | 100 | 2022-04-01 | 2026-05-01 |
| Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL Zanubrutinib, Fludarabine, cyclophosphamide and rituximab, Zanubrutinib, bendamustine, rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 63 | 2022-03-22 | 2022-03-31 |
| Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Chidamide, Azacitidine, Venetoclax - Acute Monocytic Leukemia, Newly Diagnosed | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 92 | 2022-03-01 | 2025-11-21 |
| Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML Cladribine Injection, Aclarubicin, G-CSF - Acute Myeloid Leukemia, Elderly Patients | Phase 2 | Unknown | Sun Yat-sen University | 34 | 2021-03-01 | 2020-12-17 |
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL Ponatinib 15 MG Oral Tablet - Acute Lymphoblastic Leukemia, Adult, Ph+ ALL | Phase 2 | Terminated | Institute of Hematology and Blood Transfusion, Czech Republic | 4 | 2021-02-16 | 2024-08-14 |
| VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma bortezomib, Lenalidomide, Dexamethasone - Myeloma, Newly Diagnosed | Phase 2 | Unknown | Sun Yat-sen University | 50 | 2020-09-25 | 2023-06-18 |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Selinexor, Temozolomide, Generic Radiation therapy (RT) - Gliosarcoma, Newly Diagnosed | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2020-07-07 | 2026-10-27 |
| Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL) Blinatumomab - Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL | Phase 2 | Completed | Institute of Hematology and Blood Transfusion, Czech Republic | 27 | 2019-05-09 | 2024-04-04 |
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Rucaparib, Nivolumab, Placebo Oral Tablet - Epithelial Ovarian Cancer, Primary Peritoneal | Phase 3 | Active not recruiting | pharmaand GmbH | 1097 | 2018-05-14 | 2025-06-24 |
| Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia assessments - Acute Leukemia, Newly Diagnosed | Recruiting | Memorial Sloan Kettering Cancer Center | 1365 | 2016-02-01 | 2026-07-24 |
Showing 20 of 23. Sign in to see all of them.
Multiple Myeloma (4) · Leukemia, Myeloid, Acute (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Pathologic Complete Response (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Diabetes Mellitus, Type 2 (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Gliosarcoma (1) · Leukemia (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Extranodal NK-T-Cell (1)
Neoplasms (20) · Neoplasms by Histologic Type (19) · Hemic and Lymphatic Diseases (15) · Hematologic Diseases (14) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Leukemia (9) · Lymphoproliferative Disorders (9) · Disease Attributes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Leukemia, Myeloid (5) · Lymphatic Diseases (5) · Blood Protein Disorders (4) · Cardiovascular Diseases (4)
Lenalidomide (3) · Azacitidine (2) · Dexamethasone (2) · daratumumab (2) · obinutuzumab (2) · venetoclax (2) · zanubrutinib (2) · Aclarubicin (1) · Bendamustine Hydrochloride (1) · Bortezomib (1) · Cladribine (1) · Commerce (1) · Cyclophosphamide (1) · Cytarabine (1) · Daunorubicin (1)
Sun Yat-sen University (3) · The First Affiliated Hospital of Soochow University (3) · Institute of Hematology & Blood Diseases Hospital, China (2) · Institute of Hematology and Blood Transfusion, Czech Republic (2) · Xuzhou Medical University (2) · AstraZeneca (1) · Chinese PLA General Hospital (1) · Fujian Medical University Union Hospital (1) · Imperial College London (1) · Memorial Sloan Kettering Cancer Center (1) · Molecular Partners AG (1) · National Cancer Institute (NCI) (1) · The First Affiliated Hospital of Xiamen University (1) · University Hospital, Grenoble (1) · iOMEDICO AG (1)
China (12) · United States (4) · Czechia (3) · France (3) · United Kingdom (3) · Australia (2) · Canada (2) · Germany (2) · Israel (2) · Italy (2) · Japan (2) · Netherlands (2) · Poland (2) · Russia (2) · South Korea (2)
Cyril Salek, MD (2) · Kailin Xu (2) · Bing Xu (1) · David Marin, Consultant Haematology (1) · Hua Wang, MD. (1) · Jianping Weng, Doctor (1) · Kevin A Camphausen, M.D. (1) · Prof Kathleen Moore, MD (1) · Prof Paul DiSilvestro, MD (1) · Roni Tamari, MD (1) · Sai Huang, Graduate (1) · Sheng-Li Xue, M.D. (1) · Shuhua Yi (1) · Wolfgang Knauf, Prof. Dr. (1)
PMID 20385986, PMID 22331940, PMID 25878120, PMID 26432046, PMID 27347812, PMID 27505637, PMID 28911074, PMID 30345884, PMID 31208944, PMID 32972802, PMID 33862001, PMID 34593565, PMID 34715071, PMID 35170751, PMID 35658487, PMID 36082969, PMID 38683145, PMID 39695768, PMID 41115469, PMID 42241921, PMID 42820722
2017 (1), 2023 (1)